NETRIS Pharma is a biotechnology company located in Lyon, France, founded in 2008. The company collaborates with partners to develop innovative cancer-fighting therapies based on cellular mechanisms identified by a renowned research group. Its unique model integrates with the Léon Bérard Cancer Center, allowing for a comprehensive approach to cancer treatment.
In December 2023, NETRIS Pharma secured a €7.50M Series A investment led by the European Innovation Council. This investment underscores the confidence in the company's vision and potential impact in the fields of biotechnology, healthcare, life sciences, and pharmaceuticals.
Their commitment to advancing cancer treatment through groundbreaking therapies and their strategic integration with a leading cancer center positions NETRIS Pharma as an innovative player in the biotechnology and pharmaceutical sectors, with the potential for significant growth and impact in the fight against cancer.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €7.50M | 1 |
|
19 Dec 2023 |
| Grant | $1.20M | - | 19 Jan 2023 | |
| Venture Round | Unknown | 1 |
|
06 Oct 2021 |
| Grant | €2.50M | 1 |
|
06 Oct 2021 |
No recent news or press coverage available for NETRIS Pharma.
We care about your data, and we'd love to use cookies make your experience better.
